PDCD1 and non-small cell lung carcinoma: In advanced NSCLC, as commented in the beginning, the survival outcomes in different studies is increased in comparison with chemotherapy, but still requires further measures in order to allow anti-PD-1 or anti-PD-L1 monoclonal antibodies to be more efficacious.